Form 4: Mural Oncology Director's Options Cancelled Post-Acquisition

Mural Oncology plc director Francis M. Cuss reports the cancellation of stock options following the company's acquisition by XRA 5 Corp. for $2.035 per share.

Summary

• Francis M. Cuss, a director of Mural Oncology plc, reported changes in beneficial ownership related to derivative securities.
• The changes stem from the acquisition of Mural Oncology plc by XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation.
• The acquisition was completed on December 5, 2025, at a cash purchase price of $2.035 per share.
• Stock options held by Mr. Cuss with exercise prices equal to or greater than the $2.035 acquisition price were cancelled and ceased to be outstanding.
• No consideration was delivered in exchange for these cancelled options.
• Cancelled options included 8,637 shares at an exercise price of $2.56, 8,462 shares at $3.35, and 15,021 shares at $3.61.
• Following the transaction, Mr. Cuss beneficially owns 0 derivative securities.

Sentiment

Score: 3

Explanation: The sentiment is negative for the reporting person due to the cancellation of out-of-the-money stock options without consideration. While the acquisition itself might be positive for shareholders who held shares, this specific filing details a negative outcome for the option holder.

Negatives

• Francis M. Cuss's stock options with exercise prices of $2.56, $3.35, and $3.61 were cancelled without any consideration.
• The cancellation occurred because these options were out-of-the-money, as their exercise prices were above the $2.035 per share acquisition price.

Future Outlook

NA

Industry Context

The acquisition of Mural Oncology plc by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, reflects ongoing consolidation within the biotechnology and oncology sectors. Such transactions often involve larger entities acquiring smaller companies for their strategic assets or pipeline, leading to adjustments in equity compensation for executives and directors.

Comparison to Industry Standards

• The acquisition price of $2.035 per share for Mural Oncology plc can be benchmarked against recent M&A transactions in the biotech/oncology sector, considering factors such as the company's pipeline, therapeutic focus, and market valuation prior to the announcement.
• The cancellation of out-of-the-money stock options during an acquisition is a standard practice in corporate M&A, aligning with typical deal structures where option holders only realize value if the acquisition price exceeds their exercise price.

Corporate Governance

Stakeholder Impact

• Shareholders: Those holding ordinary shares would have received a cash payment of $2.035 per share.
• Option Holders (specifically Francis M. Cuss): Options with exercise prices above the acquisition price were cancelled without value, negatively impacting their personal equity holdings.

Key Dates

Keywords

Mural Oncology, MURA, SEC Form 4, beneficial ownership, stock options, acquisition, XRA 5 Corp, XOMA Royalty Corporation, insider transaction, corporate governance